Takeda Pharmaceutical Company Limited (TYO:4502)
Japan flag Japan · Delayed Price · Currency is JPY
4,314.00
+62.00 (1.46%)
May 30, 2025, 3:30 PM JST

Revenue by Product

Fiscal year is April - March.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2013 - 2020
Gastroenterology Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Gastroenterology Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
PDT Immunology Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
PDT Immunology Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Oncology Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Oncology Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other Product Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Other Product Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Rare Metabolic
-
Log In
Log In
Log In
Log In
Upgrade
Rare Metabolic Growth
-
Log In
Log In
Log In
Log In
Upgrade
Rare Hematology
-
Log In
Log In
Log In
Log In
Upgrade
Rare Hematology Growth
-
Log In
Log In
Log In
Log In
Upgrade
Hereditary Angioedema
-
Log In
Log In
Log In
Log In
Upgrade
Hereditary Angioedema Growth
-
Log In
Log In
Log In
Log In
Upgrade
Rare Genetics and Other
-
Log In
Log In
Log In
Log In
Upgrade
Rare Genetics and Other Growth
-
Log In
Log In
Log In
Log In
Upgrade
Total Rare Diseases Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Upgrade
Total Rare Diseases Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
Upgrade
Other Rare Disease
-
Log In
Log In
Log In
Log In
Upgrade
GI Revenue (Post-FY2024 Reporting)
1,357.00B
Log In
Log In
Log In
Log In
Upgrade
GI Revenue (Post-FY2024 Reporting) Growth
11.58%
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Revenue (Post-FY2024 Reporting)
752.80B
Log In
Log In
Log In
Log In
Upgrade
Rare Diseases Revenue (Post-FY2024 Reporting) Growth
9.36%
Log In
Log In
Log In
Log In
Upgrade
PDT Revenue (Post-FY2024 Reporting)
1,032.70B
Log In
Log In
Log In
Log In
Upgrade
PDT Revenue (Post-FY2024 Reporting) Growth
14.27%
Log In
Log In
Log In
Log In
Upgrade
Oncology Revenue (Post-FY2024 Reporting)
560.40B
Log In
Log In
Log In
Log In
Upgrade
Oncology Revenue (Post-FY2024 Reporting) Growth
21.19%
Log In
Log In
Log In
Log In
Upgrade
Vaccines
55.40B
Log In
Log In
Log In
Log In
Upgrade
Vaccines Growth
9.92%
Log In
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Post-FY2024 Reporting)
565.80B
Log In
Log In
Log In
Log In
Upgrade
Neuroscience Revenue (Post-FY2024 Reporting) Growth
-9.76%
Log In
Log In
Log In
Log In
Upgrade
Other Product Revenue (Post-FY2024 Reporting)
257.40B
Log In
Log In
Log In
Log In
Upgrade
Other Product Revenue (Post-FY2024 Reporting) Growth
-18.47%
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Fiscal year is April - March.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2013 - 2020
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2013 - 2020
Japan
418.50B
Log In
Log In
Log In
Log In
Upgrade
Japan Growth
-7.29%
Log In
Log In
Log In
Log In
Upgrade
United States
2,379.70B
Log In
Log In
Log In
Log In
Upgrade
United States Growth
8.38%
Log In
Log In
Log In
Log In
Upgrade
Europe and Canada
1,055.30B
Log In
Log In
Log In
Log In
Upgrade
Europe and Canada Growth
9.15%
Log In
Log In
Log In
Log In
Upgrade
Latin America
235.80B
Log In
Log In
Log In
Log In
Upgrade
Latin America Growth
19.03%
Log In
Log In
Log In
Log In
Upgrade
Asia (ex-Japan)
291.10B
Log In
Log In
Log In
Log In
Upgrade
Asia (ex-Japan) Growth
11.44%
Log In
Log In
Log In
Log In
Upgrade
Russia / CIS
72.40B
Log In
Log In
Log In
Log In
Upgrade
Russia / CIS Growth
-0.27%
Log In
Log In
Log In
Log In
Upgrade
Other Geographic
128.80B
Log In
Log In
Log In
Log In
Upgrade
Other Geographic Growth
9.23%
Log In
Log In
Log In
Log In
Upgrade
China
191.70B
Log In
Log In
Log In
Log In
Upgrade
Asia (ex-Japan & China)
99.40B
Log In
Log In
Log In
Log In
Upgrade